Wax, Emulsifying
drugOn this page
Also known as BuffCoconut oilunhydrogenatedEmulfinEmulsifEmulsifying waxEpadermH.e.b.Lanette waxLanette wax sxOilcoconutcocntWaxemulsifying
Summary
Wax, Emulsifying (CHEMBL2108813) is a phase-3 clinical-stage unknown; indicated across 7 conditions including autism spectrum disorder and severe acute respiratory syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 7 conditions
- Clinical trials: 31
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108813 |
| Name | Wax, Emulsifying |
| Type | Unknown |
| Max phase | 3 |
Also known as: Buff, Coconut oil, unhydrogenated, Emulfin, Emulsif, Emulsifying wax, Epaderm, H.e.b., Lanette wax, Lanette wax sx, Oil, coconut
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| autism spectrum disorder | 2 | MONDO:0005258 | EFO:0003756 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| stomatitis | 2 | MONDO:0004842 | EFO:1001904 |
| Alzheimer disease | 2 | MONDO:0004975 | MONDO:0004975 |
| leprosy | 1 | MONDO:0005124 | EFO:0001054 |
| interstitial cystitis | 1 | MONDO:0018301 | EFO:0008507 |
| multiple sclerosis | 1 | MONDO:0005301 | MONDO:0005301 |
Clinical trials
Total trials: 31.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 25 |
| EARLY_PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07100145 | PHASE4 | NOT_YET_RECRUITING | Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus |
| NCT04845217 | PHASE1/PHASE2 | RECRUITING | Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome |
| NCT03740295 | PHASE2 | COMPLETED | Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis |
| NCT01381354 | PHASE1 | COMPLETED | Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) |
| NCT03185169 | EARLY_PHASE1 | TERMINATED | GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors |
| NCT07175090 | EARLY_PHASE1 | COMPLETED | Evaluation of Coconut Oil Mouth Rinse on Periodontal Parameters |
| NCT06818370 | Not specified | RECRUITING | The Effect of Coconut Oil on Alopecia |
| NCT07493434 | Not specified | ENROLLING_BY_INVITATION | Evaluation of Pain Thresholds in Migraine Patients After Inhalation of Essential Oils: a Randomized Clinical Trial |
| NCT07550023 | Not specified | RECRUITING | Effects Of Dietary Fats on Gut Microbiota Composition and Metabolic Activity in Healthy Adults |
| NCT00941837 | Not specified | COMPLETED | Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels |
| NCT01250275 | Not specified | COMPLETED | Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease |
| NCT01876394 | Not specified | UNKNOWN | Comparison of Dietary Fats on Vascular Parameters |
| NCT01962844 | Not specified | UNKNOWN | Coconut Oil in Cardiovascular Disease |
| NCT02679222 | Not specified | COMPLETED | Comparing the Ketogenic Effect of Coconut Oil and Different MCTs |
| NCT02809235 | Not specified | WITHDRAWN | Fatty Acids in Airway Smooth Muscle of Asthmatics |
| NCT03105947 | Not specified | COMPLETED | Trial of Different Dietary Fats on Blood Lipids and Metabolic Measures in Healthy Participants |
| NCT03176368 | Not specified | UNKNOWN | Coconut Oil: Managing Radiation-Induced Xerostomia |
| NCT03202654 | Not specified | COMPLETED | Effects of Corn and Coconut Oils on Lipoprotein Lipids, Insulin Sensitivity and Inflammation |
| NCT03401281 | Not specified | UNKNOWN | Trial of Different Dietary Fat Sources on Blood Lipids and Other CVD Risk Factors |
| NCT03727386 | Not specified | COMPLETED | The Effect of Vegetable Oil on Cognitive Functions of MCI Patients |
| NCT03738163 | Not specified | COMPLETED | A Clinical Investigation With Epaderm® Cream |
| NCT03904433 | Not specified | COMPLETED | Quantification of Ketosis After Intake of Coconut Oil and Caprylic Acid-With and Without Glucose-After a 12-hour Fast |
| NCT04245332 | Not specified | SUSPENDED | Effects of Fish Oil and Resistance Training on Muscle Mass and Function |
| NCT04842786 | Not specified | UNKNOWN | Topical Coconut Oil Application and Incidence of Sepsis in Neonates |
| NCT05264233 | Not specified | COMPLETED | The Acute Effects of Meals Rich in Saturated or Unsaturated Fatty Acids on Postprandial Lipaemia in Healthy Men |
| NCT05539742 | Not specified | COMPLETED | Comparison of the Effect of MCFA and LCFA on Postprandial Appetite and Lipemia |
| NCT05653362 | Not specified | COMPLETED | Coconut Oil vs. Commercial Ultrasound Gel In Obstetric Ultrasounds |
| NCT05849571 | Not specified | COMPLETED | Investigation of the Effect of Oral Care With Coconut Oil on the Degree of Oral Mucositis in Pediatric Oncology Patients |
| NCT06049589 | Not specified | COMPLETED | Therapeutic Application of Coconut Oil in Oral Health |
| NCT06379516 | Not specified | COMPLETED | Process Validation in Dermatology: Assessing Wound Creation Methods and Treatment Efficacy |
| NCT06640036 | Not specified | COMPLETED | FILIP: Fat Intake, Inflammation and LIPids |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.